# Joint Acidosis and GPR68 Signaling in Osteoarthritis: Implications for Cartilage Gene Regulation

## TL;DR

This paper explores how joint acidosis and the GPR68 receptor influence cartilage changes in osteoarthritis, suggesting GPR68 may help cells adapt to acidic conditions.

## Contribution

The paper identifies GPR68 as a proton sensor in osteoarthritis joints and suggests it may mediate adaptive responses to acidic microenvironments.

## Key findings

- GPR68 is activated in acidic conditions typical of osteoarthritis and is linked to key signaling pathways.
- Pharmacologic activation of GPR68 can suppress IL1β-induced MMP13 in chondrocytes under acidic conditions.
- GPR68 expression increases in OA cartilage and correlates with matrix turnover.

## Abstract

Joint acidosis is increasingly recognized as an important determinant of cellular behavior in osteoarthritis (OA). Declines in extracellular pH (pHe) occur across cartilage, meniscus, synovium, and subchondral bone, where they influence inflammation, matrix turnover, and pain. Among proton-sensing G protein-coupled receptors, GPR68 responds to the acidic pH range characteristic of human OA joints. The receptor is activated between pH 6.8 and 7.0, couples to Gq/PLC-MAPK, cAMP-CREB, G12/13-RhoA-ROCK signaling pathways, and is expressed most prominently in articular cartilage, with additional expression reported in synovium, bone, vasculature, and some neuronal populations. These pathways regulate transcriptional programs relevant to cartilage stress responses, inflammation, and matrix turnover. GPR68 expression is increased in human OA cartilage and aligns with regions of active matrix turnover. We previously reported that pharmacologic activation of GPR68 suppresses IL1β-induced MMP13 expression in human chondrocytes under acidic conditions, indicating that increased GPR68 expression may represent a microenvironment-responsive, potentially adaptive signaling response rather than a driver of cartilage degeneration. Evidence from intestinal, stromal, and vascular models demonstrates that GPR68 integrates pH changes with inflammatory and mechanical cues, providing mechanistic context, although these effects have not been directly established in most joint tissues. Small-molecule modulators, including the positive allosteric agonist Ogerin and the inhibitor Ogremorphin, illustrate the tractability of GPR68 as a drug target, although no GPR68-directed therapies have yet been evaluated in preclinical models of OA. Collectively, current data support GPR68 as a functionally relevant proton sensor within the acidic OA joint microenvironment.